Reinventing
Biopharma

Roivant is focused on rapidly developing innovative medicines through a novel form of industrial organization in R&D.

About Roivant

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology.

The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions.

In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

 

Founder and CEO Vivek Ramaswamy at Roivant Sciences Second Annual Pipeline Day

Myovant

Bringing new solutions to women’s health and prostate cancer

Immunovant

Enabling normal lives for patients with autoimmune diseases

Axovant

Driving innovation in neurology

Enzyvant

Developing transformative therapies for patients with rare diseases

Urovant

Improving quality of life through advancements in urology

Aruvant

Developing gene therapies for hematological conditions

Altavant

Elevating patient-centric drug development

Dermavant

Leading innovation in medical dermatology

Spirovant

Leading the revolution in treating genetic lung diseases

Respivant

Serving patients suffering from respiratory diseases

Metavant

Looking beyond the current options for cardiometabolic disorders

Genevant

Delivering results through RNA therapeutics

Sinovant

Bringing medical innovation to China

Cytovant

Developing novel and innovative cellular therapeutics in Asia

Datavant

Organizing the world's healthcare data

Alyvant

Using data to connect patients to therapies

OUR WORK

Pipeline

We have a diverse pipeline of over 45 investigational drugs in 14 therapeutic areas across our family of companies.

COMPANY
COMPOUND
INDICATION
PHASE
Company Compound Indication PRECLIN Phase 1 Phase 2 Phase 3
ENZYVANT RVT-802

Pediatric Congenital Athymia

3

MYOVANT RELUGOLIX

Prostate Cancer

3

Uterine Fibroids

3

UROVANT VIBEGRON

Overactive Bladder

3

Overactive Bladder in Men with BPH

3

DERMAVANT TAPINAROF

Psoriasis

3

MYOVANT RELUGOLIX

Endometriosis

3

SINOVANT LEFAMULIN

Community-Acquired Pneumonia

3

DERAZANTINIB

Intrahepatic Cholangiocarcinoma

3

SNV-003

Delayed Graft Function

3

Acute Kidney Injury

2

LEFAMULIN

ABSSSI

2

NARONAPRIDE

Constipation

2

ALTAVANT RODATRISTAT ETHYL

Pulmonary Arterial Hypertension

2

ARUVANT ARU-1801

Sickle Cell Disease

2

AXOVANT AXO-LENTI-PD

Parkinson's Disease

2

CYTOVANT CVT-DC-01

Acute Myeloid Leukemia

2

DERMAVANT CERDULATINIB

Vitiligo

2

TAPINAROF

Atopic Dermatitis

2

IMMUNOVANT IMVT-1401

Myasthenia Gravis

2

Graves’ Ophthalmopathy

2

METAVANT RVT-1501

Diabetes

2

RVT-1502

Diabetes

2

MYOVANT MVT-602

Female Infertility

2

RESPIVANT RVT-1601

IPF with Chronic Cough

2

UROVANT VIBEGRON

IBS-Associated Pain

2

AXOVANT AXO-AAV-GM1

GM1 Gangliosidosis

2

AXO-AAV-GM2

Tay-Sachs and Sandhoff Diseases

2

Arbutus AB-729

Hepatitis B

1

ALTAVANT RODATRISTAT ETHYL

Idiopathic Pulmonary Fibrosis

1

Sarcoidosis

1

DERMAVANT DMVT-504

Primary Focal Hyperhidrosis

1

CERDULATINIB

Atopic Dermatitis

1

UROVANT URO-902

Overactive Bladder

1

IMMUNOVANT IMVT-1401

Warm Autoimmune Hemolytic Anemia

1

Arbutus AB-452

Hepatitis B

Preclin

CYTOVANT CVT-TCR-01

Oncologic Malignancies

Preclin

DERMAVANT DMVT-501

Atopic Dermatitis

Preclin

DMVT-503

Acne Vulgaris

Preclin

ENZYVANT RVT-801

Acid Ceramidase Deficiency

Preclin

GENEVANT Additional pan-RNA Programs

Genetic Disorders

Preclin

5 mRNA Programs

Rare Diseases

Preclin

ARUVANT ARU-1801

β-Thalassemia

Preclin

SPIROVANT SPIRO-2101

Cystic Fibrosis

Preclin

SPIRO-2102

Cystic Fibrosis

Preclin

OUR PEOPLE

Leadership

Our leadership team includes industry veterans as well as exceptional leaders from outside of pharma.

The management teams of our subsidiary companies feature some of the most accomplished executives in the biopharmaceutical industry.

Our directors have deep experience in pharmaceutical business development, academic research, public policy, and life sciences investing.

Members of our Public Stakeholder Advisory Group (PSAG) provide ongoing advice on how Roivant can play a role in improving the healthcare system.

WHO WE WORK WITH

Partners

We build our Vants through partnerships with companies and academic institutions that share our commitment to developing new medicines for patients and delivering innovation in healthcare. Roivant announced in October 2019 that it has signed a definitive agreement with Sumitomo Dainippon Pharma to enter into a strategic alliance to deliver promising new medicines to patients. Other select partners are listed below.

STAY INFORMED

News

GET IN TOUCH

Contact Us

Roivant Sciences, Inc.
320 West 37th Street
6th Floor
New York, NY 10018
United States

Axovant Gene Therapies, Inc.
Eleven Times Square
33rd Floor
New York, NY 10036
United States
Roivant Sciences, Inc.
324 Blackwell Street
Bay 11, Suite 1160
Durham, NC 27701
United States

Altavant Sciences, Inc.
6501 Weston Parkway
Suite 330
Cary, NC 27513
United States
Urovant Sciences, Inc.
5281 California Avenue
Suite 100
Irvine, CA 92617
United States

Dermavant Sciences, Inc.
3780 Kilroy Airport Way
Suite 250
Long Beach, CA 90806
United States
Aruvant Sciences, Inc.
3825 Edwards Road #103
Cincinnati, OH 45209
United States
Genevant Sciences Corp.
887 Great Northern Way
Unit 155
Vancouver, BC V5T 4T5
Canada
Roivant Sciences GmbH
Viaduktstrasse 8
4051 Basel
Switzerland
Myovant Sciences, Inc.
2000 Sierra Point Parkway
9th Floor
Brisbane, CA 94005
United States

Datavant, Inc.
755 Sansome Street
2nd Floor
San Francisco, CA 94111
United States
Respivant Sciences, Inc.
11455 El Camino Real
Suite 460
San Diego, CA 92130
United States
Enzyvant Therapeutics, Inc.
55 Cambridge Parkway
Suite 102W
Cambridge, MA 02142
United States

Genevant Sciences, Inc.
245 Main Street
2nd Floor
Cambridge, MA 02142
United States
Sinovant Sciences
Room 1205-1206, Building 1, China Trade Center
81 Jianguo Road, Chaoyang District
Beijing 100025
China

Sinovant Sciences
28th Floor, Building B, The New Bund World Trade Center (phase I)
No.5, Lane 255, Dongyu Road, Pudong New Area District
Shanghai 200126
China